Published Reported
FDA May Deschedule Testosterone: What It Means (2026)
An FDA expert panel recommended removing testosterone's Schedule III controlled substance status and expanding FDA-approved indications to age-related low testosterone.
In The News
Published Reported
An FDA expert panel recommended removing testosterone's Schedule III controlled substance status and expanding FDA-approved indications to age-related low testosterone.
Published Reported
All exogenous testosterone suppresses spermatogenesis, and for patients who wish to preserve fertility, off-label clomiphene, hCG or enclomiphene may be considered.
Published Reported
A deuterated testosterone designed to resist aromatization showed a 1,000-fold potential to reduce breast cancer cell proliferation compared with standard testosterone, which may reduce estradiol-driven risks in women.
Shared Decision Making
Use our patient resources and questionnaires to prepare questions about symptoms, testing and treatment options for your doctor.
Create a free account or log in to save and bookmark articles.